1 unchanged sentence
Recent sales of unregistered securities
−Removed: From January 1, 2020 through March 31, 2020, we issued and sold to 14 employees an aggregate of 35,501 shares of common stock upon the exercise of stock options under our 2017 Stock Option and Grant Plan at a weighted-average per share exercise price of $2.33.
−Removed: The common stock issued upon the exercise of options described above were issued under our 2017 Stock Option and Grant Plan in reliance on the exemption provided by Rule 701 promulgated under the Securities Act.
−Removed: The recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us.
−Removed: The foregoing transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering.
+Added: On July 21, 2020, pursuant to the Bio Palette License Agreement, we issued 175,000 shares of our common stock to Bio Palette in satisfaction of certain milestone payment obligations pursuant to the Bio Palette License Agreement.
+Added: We relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof, for a transaction by an issuer not involving any public offering.
Use of proceeds from registered securities
12 unchanged sentences
There has been no material change in our planned use of the net proceeds from our IPO described in our final prospectus, dated February 5, 2020, filed with the SEC pursuant to Rule 424(b) relating to our Registration Statement on Form S-1.
+Added: If Incorporated by Reference
+Added: Description of Exhibit
+Added: Fourth Amended Certificate of Incorporation of Beam Therapeutics Inc.
+Added: Amended and Restated By-laws of Beam Therapeutics Inc.
+Added: Lease Agreement between Beam Therapeutics Inc.
+Added: and ARE-NC Region No.
+Added: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: XBRL Instance Document
+Added: XBRL Taxonomy Extension Schema Document
+Added: XBRL Taxonomy Calculation Linkbase Document
+Added: XBRL Taxonomy Extension Definition Linkbase Document
+Added: XBRL Taxonomy Label Linkbase Document
+Added: XBRL Taxonomy Presentation Linkbase Document
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: BEAM THERAPEUTICS INC.
+Added: August 12, 2020
+Added: /s/ John Evans
+Added: Chief Executive Officer
+Added: (Principal executive officer)
+Added: August 12, 2020
+Added: /s/ Terry-Ann Burrell
+Added: Terry-Ann Burrell
+Added: Chief Financial Officer and Treasurer
+Added: (Principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.